Structure Therapeutics Inc. Sponsored ADR (GPCR)
(Real Time Quote from BATS)
$16.72 USD
-0.06 (-0.36%)
Updated Aug 5, 2025 02:06 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GPCR 16.72 -0.06(-0.36%)
Will GPCR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for GPCR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GPCR
LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study
NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback
GPCR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Best Momentum Stocks to Buy for October 23rd
Does Structure Therapeutics Inc. Sponsored ADR (GPCR) Have the Potential to Rally 115.8% as Wall Street Analysts Expect?
NVO Oral Obesity Pill Tops Wegovy; LLY, VKTX, GPCR Stocks Rise
Other News for GPCR
Structure Therapeutics (GPCR) Gains Analyst Support with Buy Rating
Structure Therapeutics initiated with bullish view at Clear Street, here's why
Goldman Sachs Initiates Coverage on Structure Therapeutics (GPCR) | GPCR Stock News
Structure Therapeutics initiated with Early-Stage Biotech at Goldman Sachs
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Gets a Buy from Guggenheim